Article in Cell chemical biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
Alexander M RealDepartment of Oncological Sciences, Department of Pharmacological Sciences, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
William M MarsigliaDepartment of Oncological Sciences, Department of Pharmacological Sciences, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Arvin C DarDepartment of Oncological Sciences, Department of Pharmacological Sciences, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: arvin.dar@mssm.edu.
Icahn School of Medicine at Mount Sinai · USTisch Hospital · US
Funding
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Deanna L Benson · 2015 to 2026
$35.4M
A New Disease Platform Leveraging Complex Drosophila and Mammalian ModelsU54OD020353 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CAGAN, ROSS LEIGH · 2015 to 2019
$10.3M
Targeting Oncogenic Ras-MAPK Signaling Complexes via the Scaffold KSRR01CA227636 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Arvin Dar · 2018 to 2026
$4.0M
Defining the relationship between kinase inhibitor pharmacophores and pro-/anti-targets using in vivo models of colorectal cancerK00CA212474 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MARSIGLIA, WILLIAM M · 2019 to 2022
$374k
Genetic and Pharmacological Manipulation of KSR in KRAS-driven CancerF30CA232454 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI REAL, ALEXANDER · 2018 to 2021
$189k
Mechanisms of resistance and activation conferred by kinases displaying hinge and gate-keeper mutationsF99CA212474 · NCI · NEW YORK UNIVERSITY · PI MARSIGLIA, WILLIAM M · 2016 to 2017
In this issue of Cell Chemical Biology, Pisa et al. (2020) find that haploid and diploid cells differentially develop resistance to the CENP-E inhibitor GSK923295. The results highlight the power of tumor cells to evade growth inhibition and potentially inform the design of next-generation CENP-E drugs to overcome resistance.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Ploidy Leads a Molecular Motor to Walk Different Paths to Drug Resistance. · full record | OpenQuestion